Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
In this Phase II trial, the investigators will evaluate the combination of gemcitabine,
carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative
breast cancer. In addition, to assess the efficacy of this combination, tumor tissue will be
examined for the presence of various markers, including K-ras and PI3K-activating mutations,
EGFR, PTEN, and p53. Correlation of tumor response with marker expression may define a
patient subset that is particularly responsive to treatment with a panitumumab-containing
combination.